Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Chemotherapy in Advanced NSCLC
NCT06467500Phase 2
Key facts
- Status
- Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Bispecific Antibodies
- Drugs
- cadonilimab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC). Primary endpoint: Objective Response Rate at 24 months. Started Mar 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Bispecific antibody plus Chemotherapy
Cadonilimab combined with gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine
03
Who it enrols
Patients with advanced NSCLC who are negative for driver genes and have failed prior anti-PD-1/PD-L1 immunotherapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Disease Control Rate
Duration of Response
Progression-free survival
Overall Survival
Adverse event
Beyond the preview
Go deeper on NCT06467500.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467500.